. 2021 Jan 7;10:604657. doi: 10.3389/fonc.2020.604657

Table 2.

Adverse events during the CCRT-CCT or CCRT-alone period.

Adverse events	Grade	No. of studies	No. of patients	Pooled OR and its 95% CI	Meta-regression(P value)	Heterogeneity
Adverse events	Grade	No. of studies	No. of patients	Pooled OR and its 95% CI	Meta-regression(P value)	I²(%)	P value
Leukopenia	0-2	2	178	0.62 (0.26-1.47)	0.28	0	0.80
Leukopenia	3-4	2	178	1.62 (0.68-3.89)	0.28	0	0.80
Thrombocytopenia	0-2	2	178	0.93 (0.18-4.76)	0.93	0	0.42
Thrombocytopenia	3-4	2	178	1.07 (0.21-5.45)	0.93	0	0.42
Neutropenia	0-2	3	702	0.86 (0.59-1.25)	0.42	0	0.89
Neutropenia	3-4	3	702	1.16 (0.80-1.68)	0.42	0	0.89
Anemia	0-2	2	178	0.93 (0.26-3.33)	0.91	0	0.50
Anemia	3-4	2	178	1.08 (0.30-3.87)	0.91	0	0.50
Gastrointestinal tract	0-2	3	702	1.35 (0.61-2.98)	0.46	0	0.95
Gastrointestinal tract	3-4	3	702	0.74 (0.34-1.64)	0.46	0	0.95
Radiation esophagitis	0-2	3	702	0.94 (0.67-1.31)	0.72	0	0.70
Radiation esophagitis	3-4	2	178	1.84 (0.42-8.01)	0.42	0	0.67
Radiation pneumonia	0-2	3	702	1.05 (0.73-1.50)	0.81	17	0.30
Radiation pneumonia	3-4	3	178	0.71 (0.12-4.31)	0.71	32	0.23

CCRT-CCT, consolidation chemotherapy following concurrent chemoradiotherapy; CCRT-alone, only concurrent chemoradiotherapy. OR, odds ratio; 95% CI, 95% confidence interval.